Table 4 Appendix comparative histopathological findings post-resection across PP, P1 and P2 groups, highlighting tumour aggressiveness and staging
PP (2019) | P1 (2020) | P2 (2021) | Total | |
|---|---|---|---|---|
Postoperative pathology T stage (p-value = 0.1359) | ||||
T0 | 10 (18.9%) | 5 (16.7%) | 11 (19%) | 26 (18.4%) |
T1 | 1 (1.9%) | 0 | 0 | 1 (0.7%) |
T1a | 2 (3.8%) | 3 (10%) | 2 (3.4%) | 7 (5%) |
T1b | 14 (26.4) | 3 (10%) | 9 (15.5%) | 26 (18.4%) |
T2 | 6 (11.3%) | 3 (10%) | 4 (6.9%) | 13 (9.2%) |
T3 | 20 (37.7%) | 11 (36.7%) | 23 (39.7%) | 54 (38.3%) |
T4 | 0 | 0 | 1 (1.7%) | 1 (0.7%) |
T4a | 0 | 5 (16.7%) | 7 (12.1%) | 12 (8.5%) |
T4b | 0 | 0 | 1 (1.7%) | 1 (0.7%) |
Numbers of lymph nodes harvested (p-value = 0.4974) | ||||
Mean | 28.49 | 30.87 | 29.44 | |
Numbers of Positive lymph nodes harvested (p-value = 0.1124) | ||||
Mean | 1.19 | 2.68 | 2.98 | |
Post-operative pathology Staging (p-value = 0.1064) | ||||
Stage 0 | 10 (18.9%) | 4 (13.3%) | 8 (14%) | 22 (15.7%) |
Stage 1 | 17 (32.1%) | 6 (20%) | 7 (12.3%) | 30 (21.4%) |
Stage 2 | 12 (22.6%) | 8 (26.7%) | 17 (29.8%) | 37 (26.4%) |
Stage 3 | 11 (20.8%) | 7 (23.3%) | 11 (19.3%) | 29 (20.7%) |
Stage 4 | 3 (5.7%) | 5 (16.7%) | 14 (24.6%) | 22 (15.7%) |
Resection margins R0/R1 (p-value = 0.04176) | ||||
R0 | 45 (84.9%) | 24 (80%) | 37 (64.9%) | 106 (75.7%) |
R1 | 8 (15.1%) | 6 (20%) | 20 (35.1%) | 34 (24. %) |